Physician profile
Cory Sehrt
NPI 1215562517
$4,269.78
in general payments reported to CMS, 2019-2025
36 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.90 · 2022: $606 · 2023: $1,655 · 2024: $1,402 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,569 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,568.74 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $840.93 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $568.90 | 2023-2025 | |
| Corium, LLC | $367.43 | 2023-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $240.85 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $235.41 | 2022-2025 | Mounjaro, Zepbound, Taltz |
| Bayer Healthcare Pharmaceuticals INC. | $173.52 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.04 | 2022-2023 | Jardiance, Trijardy Xr |
| Pfizer INC. | $156.16 | 2023-2025 | |
| Glaxosmithkline, LLC. | $131.41 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $121.32 | 2022-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $115.82 | 2022-2025 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $107.69 | 2022-2023 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $80.86 | 2024 | Dupixent |
| Dexcom, INC. | $79.30 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $70.32 | 2022-2024 | Repatha, Otezla |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.60 | 2022-2023 | Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $63.81 | 2022-2025 | |
| Genzyme Corporation | $63.24 | 2024 | |
| Sumitomo Pharma America, INC. | $60.22 | 2024-2025 | Gemtesa |
| Biogen, INC. | $59.14 | 2023-2024 | Skyclarys, Skyclarys |
| Janssen Pharmaceuticals, INC | $58.54 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $57.37 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $55.30 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $50.68 | 2024-2025 | Nexletol |
| Verona Pharma, INC. | $41.62 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $40.59 | 2024 | Zoryve |
| Janssen Biotech, INC. | $35.26 | 2024 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $26.44 | 2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $22.48 | 2024 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.80 | 2025 | Caplyta |
| Leo Pharma INC. | $20.25 | 2024 | Adbry |
| Ucb, INC. | $17.72 | 2024 | Bimzelx |
| Ardelyx, INC. | $13.53 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.13 | 2024 | Xifaxan |
| Nevro Corp. | $12.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Sehrt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.